pSivida heralds 'image-raising' appointments
06 March, 2002 by Daniella GoldbergPlatform technology company pSivida has made two new appointments to raise its international profile.
Strong growth continues for PanBio
06 March, 2002 by Pete YoungDiagnostic test company PanBio posted a first half sales jump of 49% to stay on track for a full year revenue target of $16.9 million.
Deloittes aims to flush out fast-moving biotechs
06 March, 2002 by Iain ScottNational accounting firm Deloittes has launched its Technology Fast 50 program for 2002.
BresaGen: stem cell debate won't affect our research
05 March, 2002 by Tanya HollisBresaGen has reassured investors its projects are not threatened by potential regulation of stem cell research in Australia.
Panbio pulls back from dendrimer joint venture
04 March, 2002 by Pete YoungA million-dollar collaboration between nano-drug company Starpharma and diagnostics specialist PanBio Ltd has come unstuck.
Cryosite poised for listing
04 March, 2002 by Daniella GoldbergCryosite, a Sydney-based biotechnology service company that stores frozen biological material, is going public.
Biota aims to reclaim position after flat half-year
04 March, 2002 by Tanya HollisBiota Holdings' much-hyped influenza drug, Relenza, failed to contribute revenue in an interim result that saw the company record a loss of $3.2 million.
Medical devices network takes shape
01 March, 2002 by Daniella GoldbergA new network for the medical device industry is gearing up for launch.
Plant breeders to get access to genetic info
01 March, 2002 by Tanya HollisPlant breeders are expected to benefit from a joint venture between a Melbourne genetics company and the Victorian Government.
GroPep offloads IP to concentrate on protein pharma
01 March, 2002 by Tanya HollisSouth Australian drug discovery company GroPep (ASX:GRO) has begun selling off sections of its newly acquired intellectual property treasure chest.
Cash injection boosts Amrad R&D program
01 March, 2002 by Tanya HollisDrug developer Amrad Corporation has raised $15.5 million in capital to help progress its clinical trials program.
R&D spend dominates BresaGen half-year
28 February, 2002 by Daniella GoldbergAustralian biotechnology company BresaGen's half-year results to December 2001 show an increase in revenue by 15 per cent, to $3,661,000, over the same period a year ago.
AgVic's genetic hens join the elites
28 February, 2002 by Tanya HollisAgriculture Victoria's 40-year bantamised hen project has entered the commercialisation phase, beginning a joint research deal with an elite international breeder.
Axon releases new drug discovery tool
28 February, 2002 by Tanya HollisA screening instrument that enables drug company technicians to run parallel tests has been released by Melbourne-based company Axon Instruments (ASX: AXN).
Shellfish gene helps Brisbane biotech
27 February, 2002 by Pete YoungBrisbane biotech business Xenome Ltd is moving closer to human trials with a pain-killing molecule derived from the venom of a marine shellfish.
